Sattva Sukun

Who are in the management team of Sattva Sukun?

As of March 2022, the management team of Sattva Sukun includes Mit Tarun Brambhatt as Managing Director (Rs. 8.1 lacs remuneration), and independent directors Khushboo Vasudev and Kanika Kabra, both with no remuneration.

As of March 2022, the management team of Sattva Sukun includes:<BR><BR>1. Mit Tarun Brambhatt - Managing Director, with a remuneration of Rs. 8.1 lacs.<BR>2. Khushboo Vasudev - Independent Director, with no remuneration.<BR>3. Kanika Kabra - Independent Director, with no remuneration.

What is the bonus history of the Sattva Sukun?

Sattva Sukun Lifecare Ltd has announced a bonus issue in a 3:5 ratio, with an ex-date of January 17, 2025, for eligible shareholders.

Sattva Sukun Lifecare Ltd has a recent bonus issue announced with a ratio of 3:5. The ex-date for this bonus is set for January 17, 2025. This means that shareholders on record as of this date will be eligible to receive the bonus shares. If you have any more questions about the company or its financial activities, feel free to ask!

Has Sattva Sukun declared dividend?

No Dividend History Available

What is the technical trend for Sattva Sukun?

As of June 2, 2025, Sattva Sukun's technical trend is mildly bearish, with bearish signals from the weekly MACD and daily moving averages, although the monthly MACD and KST suggest some potential for recovery.

As of 2 June 2025, the technical trend for Sattva Sukun has changed from bearish to mildly bearish. The weekly MACD remains bearish, while the monthly MACD shows a mildly bullish stance, indicating some potential for recovery. The daily moving averages are bearish, reinforcing the short-term negative sentiment. The Bollinger Bands are bearish on both weekly and monthly time frames, suggesting continued downward pressure. The KST is mildly bullish on both weekly and monthly charts, providing a slight counterbalance. Overall, the current technical stance is mildly bearish, with key indicators such as the weekly MACD and daily moving averages driving this assessment.

Why is Sattva Sukun falling/rising?

As of 10-Jun, Sattva Sukun Lifecare Ltd's stock price is 1.13, up 1.8% recently but down 8.87% over the past month and 10.22% year-to-date. Despite positive quarterly results, the stock's long-term fundamentals are weak, and investor participation has declined significantly.

As of 10-Jun, Sattva Sukun Lifecare Ltd's stock price is currently at 1.13, reflecting an increase of 0.02 or 1.8%. The stock has shown a positive trend recently, gaining for the last three consecutive days with a total return of 4.63% during this period. Despite this short-term gain, the stock has underperformed over the past month, down 8.87%, and year-to-date, it has decreased by 10.22%. The company has reported positive results for the last three quarters, including a highest Return on Capital Employed (ROCE) of 13.15% and a significant increase in profits, which may contribute to the recent uptick in stock price. However, the stock's long-term fundamentals are weak, evidenced by a low Return on Equity (ROE) of 6.27% and a concerning EBIT to Interest ratio of 1.28, indicating challenges in servicing debt.<BR><BR>In the broader market context, the stock's recent performance has outpaced the sector by 2.86%, although it still lags behind the benchmark Sensex, which has risen by 2.05% over the past week. The stock's liquidity remains adequate, but there has been a notable decline in investor participation, with delivery volume falling by 42.52% against the five-day average. While the stock has generated a commendable return of 31.69% over the past year, the overall market has also performed well, with the BSE 500 returning 6.22%. This contrast highlights the stock's volatility and the mixed signals from its financial health and market performance.

Who are the peers of the Sattva Sukun?

Sattva Sukun's peers include MRP Agro, Novelix Pharma, Kotia Enterprise, and others. In terms of performance, Novelix Pharma leads with a 1-year return of 138.43%, while Sattva Sukun has a return of 9.74%.

Peers: The peers of Sattva Sukun are MRP Agro, Novelix Pharma., Kotia Enterprise, Ace Men, Radhagobind Comm, Fonebox Retail, Cell Point, Magson Retail, Silgo Retail, and Purv Flexi.<BR><BR>Quality Snapshot: Excellent management risk is observed at Fonebox Retail, while Good management risk is found at MRP Agro and Magson Retail, and the rest have Below Average management risk. Excellent growth is noted at Sattva Sukun and Fonebox Retail, while Good growth is seen at MRP Agro and the rest have Below Average growth. Good capital structure is present at MRP Agro, Sattva Sukun, and Magson Retail, while the rest have Below Average or do not qualify.<BR><BR>Return Snapshot: Novelix Pharma. has the highest 1-year return at 138.43%, while MRP Agro has the lowest at -2.56%. Sattva Sukun's 1-year return of 9.74% is higher than MRP Agro's but lower than Novelix Pharma.'s. Additionally, peers such as MRP Agro, Ace Men, and Silgo Retail have negative six-month returns.

What does Sattva Sukun do?

Sattva Sukun Lifecare Ltd is a micro-cap retail company involved in trading equities and providing loans, with a market cap of INR 58 Cr and reported net sales of 10 Cr and net profit of 8 Cr for March 2025. The company was incorporated in 1980 and has undergone several name changes, with its latest being in 2015.

Overview:<BR>Sattva Sukun Lifecare Ltd operates in the retailing industry as a micro-cap company, primarily involved in trading and investing in equities as well as providing loans and advances.<BR><BR>History:<BR>The company was incorporated in August 1980 and was originally known as Mayukh Commercial Ltd. It changed its name to Mayukh Dealtrade Limited on November 5, 2015. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 10 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 8 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 58 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 23.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.02<BR>- Return on Equity: 10.39%<BR>- Price to Book: 2.41<BR><BR>Contact Details:<BR>Address: Shop No 38 Rock Avenue Plot E, CHS Ltd Charkop Kandivali (W) Mumbai Maharashtra: 400067<BR>Email: info@mayukh.co.in<BR>Website: http://www.mayukh.co.in

Who are the top shareholders of the Sattva Sukun?

The top shareholders of Sattva Sukun include Roshan Dealmark Private Limited with 3.59% and public shareholder Kanabar Parag Suresh with 5%. Individual investors hold a significant 78.96%, with no pledged promoter holdings or mutual funds/foreign institutional investors involved.

The top shareholders of Sattva Sukun include Roshan Dealmark Private Limited, which holds the highest promoter stake at 3.59%. The highest public shareholder is Kanabar Parag Suresh, who owns 5% of the shares. Additionally, individual investors collectively hold a significant 78.96% of the company's shares. Notably, there are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares.

How big is Sattva Sukun?

As of 24th July, Sattva Sukun Lifecare Ltd has a market capitalization of 28.00 Cr, classifying it as a Micro Cap company, with recent Net Sales of 5.27 Cr and a Net Profit of 2.49 Cr. Specific values for Shareholder's Funds and Total Assets are unavailable.

As of 24th July, Sattva Sukun Lifecare Ltd has a market capitalization of 28.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Sattva Sukun reported Net Sales of 5.27 Cr and a Net Profit of 2.49 Cr.<BR><BR>The reporting period for the balance sheet data is the latest annual period, but specific values for Shareholder's Funds and Total Assets are not available.

How has been the historical performance of Sattva Sukun?

Sattva Sukun has shown significant growth from March 2020 to March 2025, with net sales increasing from 0.43 Cr to 5.26 Cr, and profit after tax rising from 0.00 Cr to 2.49 Cr, reflecting strong operational performance and enhanced shareholder value.

Answer:<BR>The historical performance of Sattva Sukun shows a significant upward trend in net sales and profitability over the years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Sattva Sukun's net sales have increased from 0.43 Cr in March 2020 to 5.26 Cr in March 2025, reflecting a strong growth trajectory. The total operating income has similarly risen, reaching 5.26 Cr in March 2025, up from just 0.43 Cr in March 2020. The company has maintained a consistent operating profit, with the operating profit (PBDIT) climbing to 3.65 Cr in March 2025 from a mere 0.07 Cr in March 2020. Profit before tax also saw a substantial increase, reaching 3.19 Cr in March 2025 compared to 0.00 Cr in March 2020. Consequently, profit after tax surged to 2.49 Cr in March 2025, up from 0.00 Cr in March 2020. The earnings per share (EPS) improved to 0.11 in March 2025 from 0.00 in March 2020, indicating enhanced shareholder value. Overall, Sattva Sukun's financial performance demonstrates robust growth across key metrics, highlighting its successful operational strategies and market positioning.

Is Sattva Sukun overvalued or undervalued?

As of November 26, 2025, Sattva Sukun is considered undervalued with a PE ratio of 8.91 and favorable financial metrics, making it an attractive investment compared to its peers, despite a year-to-date return of -45.97%.

As of 26 November 2025, the valuation grade for Sattva Sukun has moved from very expensive to very attractive, indicating a significant shift in its perceived value. The company is currently considered undervalued based on its financial metrics, with a PE ratio of 8.91, an EV to EBIT of 7.91, and an EV to EBITDA of 7.03. These ratios suggest that the stock is trading at a lower valuation compared to its earnings and cash flow generation capabilities.<BR><BR>In comparison to its peers, Sattva Sukun's PE ratio is notably lower than that of Elitecon International, which stands at 217.83, and MMTC at 130.85, both categorized as very expensive. Additionally, PTC India, another peer considered very attractive, has a PE ratio of 7.37, further supporting the argument that Sattva Sukun is undervalued. Despite recent stock performance trailing behind the Sensex, with a year-to-date return of -45.97% compared to the Sensex's 9.56%, the current valuation metrics suggest that Sattva Sukun presents a compelling investment opportunity.

When is the next results date for Sattva Sukun Lifecare Ltd?

The next results date for Sattva Sukun Lifecare Ltd is 19 February 2026.

The next results date for Sattva Sukun Lifecare Ltd is scheduled for 19 February 2026.

Are Sattva Sukun Lifecare Ltd latest results good or bad?

Sattva Sukun Lifecare Ltd's latest Q3 FY26 results are concerning, showing a net loss of ₹0.69 crores and a 66.21% drop in revenue to ₹5.69 crores, indicating significant operational challenges despite a year-on-year revenue growth of 190.31%. Investors should be cautious as the company's financial stability appears compromised.

Sattva Sukun Lifecare Ltd's latest results for Q3 FY26 indicate a troubling performance. The company reported a net loss of ₹0.69 crores, which is a significant decline of 188.46% compared to the previous quarter's profit of ₹0.78 crores. Additionally, revenue fell sharply by 66.21% to ₹5.69 crores from ₹16.84 crores in Q2 FY26. This drastic drop in both revenue and profitability raises concerns about the company's operational stability.<BR><BR>The PAT margin has also deteriorated, collapsing to -12.13% from a positive 4.63% in the prior quarter. Such a significant decline in performance suggests that the company is facing serious challenges, potentially related to cost management or market conditions.<BR><BR>While the year-on-year revenue growth of 190.31% may seem impressive, it is overshadowed by the recent volatility and losses. The overall financial picture indicates that Sattva Sukun is struggling, making the latest results appear quite negative. Investors should be cautious, as the company’s ability to return to profitability in the upcoming quarters will be critical for restoring confidence.

Should I buy, sell or hold Sattva Sukun Lifecare Ltd?

Which are the latest news on Sattva Sukun?